ZUO LI YAO YE(SZ:300181)2023-07-07 15:26Sales Performance - The sales of Wuling capsules and Lingze tablets showed good growth in Q2, benefiting from the normalization of hospital meetings post-pandemic [1] - Lingze tablets have been recommended in 12 clinical guidelines and expert consensus, with sales exceeding 100 million CNY in 2021, reflecting a growth rate of 68.42% [2] - In Q1 of this year, sales volume and revenue for Lingze tablets increased by 33.54% and 34.09% respectively [2] Market Potential - The company aims for Lingze tablets to achieve a sales target of 500 million CNY, with a long-term goal of reaching 1 billion CNY [2] - The market for Lingze tablets is promising due to the promotion of combined traditional and Western medicine treatments [2] Hospital Development - The company has covered over 10,000 hospitals with Wuling capsules, with more than 50% being primary hospitals and community health centers [3] - Lingze tablets have been introduced to over 1,000 hospitals, primarily in urology, male health, and geriatrics [3] - The company is actively expanding its hospital network, leveraging its status as a successful bidder in centralized procurement [3] Financial Management - The company is managing sales expenses dynamically, anticipating a decrease in sales expense rates as products mature [3] - The overall gross profit margin remains stable, with efforts to reduce costs on both production and sales fronts [3] Product Development - The company is cultivating the potential of Jukapobofe calcium tablets, which have a significant market size in East Asia [4] - The production capacity for Wuling mycelium powder is set to increase from 600 tons to 900 tons, supporting an estimated output value of 2.5 billion CNY [4] Sales Team Structure - The sales team has seen minimal changes in recent years, with a slight increase in numbers this year [5] - The company employs a self-operated model for its sales team, ensuring effective training and management [5]